Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

V.B.C. Biemans^*, F. Hoentjen, M.J. Pierik

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	92-92
Number of pages	1
Journal	New England Journal of Medicine
Volume	382
Issue number	1
DOIs	https://doi.org/10.1056/NEJMc1915739
Publication status	Published - 2 Jan 2020

Access to Document

@article{836027224acc44f6b44e723e8797d679,

title = "Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis",

author = "V.B.C. Biemans and F. Hoentjen and M.J. Pierik",

year = "2020",

month = jan,

day = "2",

doi = "10.1056/NEJMc1915739",

language = "English",

volume = "382",

pages = "92--92",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "MASSACHUSETTS MEDICAL SOCIETY",

number = "1",

}

TY - JOUR

T1 - Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

AU - Biemans, V.B.C.

AU - Hoentjen, F.

AU - Pierik, M.J.

PY - 2020/1/2

Y1 - 2020/1/2

U2 - 10.1056/NEJMc1915739

DO - 10.1056/NEJMc1915739

M3 - Comment/Letter to the editor

SN - 0028-4793

VL - 382

SP - 92

EP - 92

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 1

ER -